Glanzmann's thrombasthenia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
{{Glanzmann's thrombasthenia}}
{{Glanzmann's thrombasthenia}}


{{CMG}} '''Associate Editor(s)-in-Chief:''' [[User:Niush.D|Niyousha Danesh, MD-MPH]]
{{CMG}}, {{AE}} {{OK}}, [[User:Niush.D|Niyousha Danesh, MD-MPH]]


==Overview==
==Overview==

Revision as of 18:46, 13 November 2018

Glanzmann's thrombasthenia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glanzmann's thrombasthenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glanzmann's thrombasthenia differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glanzmann's thrombasthenia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glanzmann's thrombasthenia differential diagnosis

CDC on Glanzmann's thrombasthenia differential diagnosis

Glanzmann's thrombasthenia differential diagnosis in the news

Blogs on Glanzmann's thrombasthenia differential diagnosis

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Glanzmann's thrombasthenia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2], Niyousha Danesh, MD-MPH

Overview

Glanzmann thrombasthenia must be differentiated from other diseases that cause severe hemorrhages , mucocutaneous bleeding , petechiae and ecchymosis, such as platelet Disorders (like : Bernard-Soulier syndrome,platelet storage pool defects,platelet-type von Willebrand disease and gray platelet syndrome), Fibrinogen abnormalities ,(eg Afibrinogenemia), Von Willebrand Disease and Wiskott-Aldrich Syndrome.

Differential Diagnoses

Differential Diagnosis

Diseases Laboratory Findings Physical Examination History and Symptoms Treatment
Bleeding Time (BT) PT aPTT Platelet count vWF Petechiae

& Purpura

Ecchymosis Mucocutaneous hemorrhage Severe fatal bleeding Epistaxis Oral bleeding Menorrhagia & Postpartum hemorrhage Infection Hemarthrosis Additional

information

Glanzmann Thrombasthenia[1] Normal (Nl) Nl lower level of Normal Nl + + + + + + + _ _ Autosomal recessive (AR)

GpIIb/IIIa receptor defect

ITGA2B and ITGB3 gene

  • Platelet aggregation responds to ristocetin but not (ADP), epinephrine, and collagen.
  • Local hemostatic procedures
  • Anti-fibrinolytic drugs
  • rFVIIa, IVIG, plasmapheresis, corticosteroids, rituximab
  • HSCT[2]
Von Willebrand disease (vWD) Nl Nl Nl + + + + + + + _ _ Autosomal dominant (AD) and autosomal recessive, AR (rare)
  • vWF
  • DDAVP
  • factor VIII concentrates[3]
Bernard-Soulier Syndrome[4] Nl

giant platelets

+ + + + + + + _ _ AR

↓GPIb/IX/V platelets

  • platelets do not aggregate in response to ristocetin but responds to ADP, epinephrine, and collagen
  • DDAVP
  • antifibrinolytic
  • rFVIIa[5]
Wiskott-Aldrich Syndrome[6] Nl Nl Nl

microthrombocytopenia

Nl + + +

(specially GI bleeding)

+ + _
  • X-linked defect in The WASp gene
  • +Severe eczema
  • antibiotics, antivirals, antifungals,
  • chemotherapy
  • immunoglobulins
  • corticosteroids
Inherited Abnormalities of Fibrinogen[7] Nl Inherited Abnormalities of Fibrinogen + + + + + + _ + Fibrinogen defect

3gene:FGA, FGB, and FGG

  • Fibrinogen concentrates
  • cryoprecipitate[8]

References

  1. Nurden AT (2006). "Glanzmann thrombasthenia". Orphanet J Rare Dis. 1: 10. doi:10.1186/1750-1172-1-10. PMC 1475837. PMID 16722529.
  2. Solh T, Botsford A, Solh M (2015). "Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options". J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.
  3. de Wee EM, Sanders YV, Mauser-Bunschoten EP, van der Bom JG, Degenaar-Dujardin ME, Eikenboom J; et al. (2012). "Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease". Thromb Haemost. 108 (4): 683–92. doi:10.1160/TH12-04-0244. PMID 22918553.
  4. Pham A, Wang J (2007). "Bernard-Soulier syndrome: an inherited platelet disorder". Arch Pathol Lab Med. 131 (12): 1834–6. doi:10.1043/1543-2165(2007)131[1834:BSAIPD]2.0.CO;2. PMID 18081445.
  5. Diz-Küçükkaya R (2013). "Inherited platelet disorders including Glanzmann thrombasthenia and Bernard-Soulier syndrome". Hematology Am Soc Hematol Educ Program. 2013: 268–75. doi:10.1182/asheducation-2013.1.268. PMID 24319190.
  6. Ochs HD, Thrasher AJ (2006). "The Wiskott-Aldrich syndrome". J Allergy Clin Immunol. 117 (4): 725–38, quiz 739. doi:10.1016/j.jaci.2006.02.005. PMID 16630926.
  7. Zhou J, Ding Q, Chen Y, Ouyang Q, Jiang L, Dai J; et al. (2015). "Clinical features and molecular basis of 102 Chinese patients with congenital dysfibrinogenemia". Blood Cells Mol Dis. 55 (4): 308–15. doi:10.1016/j.bcmd.2015.06.002. PMID 26460252.
  8. Verhovsek M, Moffat KA, Hayward CP (2008). "Laboratory testing for fibrinogen abnormalities". Am J Hematol. 83 (12): 928–31. doi:10.1002/ajh.21293. PMID 18951466.